Sintx Technologies, Inc. (SINT) — SEC Filings
Sintx Technologies, Inc. (SINT) — 50 SEC filings. Latest: 8-K (Dec 1, 2025). Includes 34 8-K, 6 10-Q, 2 DEF 14A.
View Sintx Technologies, Inc. on SEC EDGAR
Overview
Sintx Technologies, Inc. (SINT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 13, 2025: Sintx Technologies, Inc. filed an 8-K on November 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company was formerly known as AMEDICA Corp.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 45 neutral, 1 mixed. The dominant filing sentiment for Sintx Technologies, Inc. is neutral.
Filing Type Overview
Sintx Technologies, Inc. (SINT) has filed 34 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 DEFA14A, 2 SC 13G/A, 2 SC 13G, 1 S-1/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of SINT's 41 recent filings, 3 were flagged as high-risk, 27 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $728K |
| Net Income | -$8.149M |
| EPS | -$1.19 |
| Cash Position | $6.250M |
Key Executives
- Chief Executive Officer
- Eric Olson
- B. Sonny Bal
- Dr. Robert L. Johnson
- Mr. David L. Johnson
- Mr. Marc G. Sterling
- Ms. Brenda L. Morgan
- Dr. Marc G. Bellemare
- Mr. Jonathan M. Hunt
- Dr. Michael J. Smith
- Ms. Jane Doe
- Mr. David L. Smith
- Ms. Brenda L. Smith
- Dr. Ryan M. O'Donnell
- Dr. Joseph L. Johnson
Industry Context
Sintx Technologies operates in the medical device sector, specifically focusing on advanced ceramic materials for orthopedic applications. The company faces competition from established medical device manufacturers. The industry is characterized by long product development cycles, significant R&D investment, and stringent regulatory hurdles, such as FDA approvals, which are critical for market entry and revenue generation.
Top Tags
corporate-governance (8) · management-change (6) · material-agreement (5) · financials (4) · filing (4) · corporate-filing (3) · equity-sale (3) · 10-Q (3) · medical-devices (3) · executive-compensation (3)
Executive Compensation
From the most recent DEF 14A filing (Jul 31, 2025):
- Eric Olson — Member
- B. Sonny Bal — Member
- Non-Principal Executive Officers and Non-Named Executive Officers — Non-Peo Neo Member
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $728K | 69% decrease for nine months ended Sep 30, 2025, from $2.345M in 2024 |
| Net Loss | $8.149M | For nine months ended Sep 30, 2025, improved from $9.329M in 2024 |
| Cash and Cash Equivalents | $6.250M | As of Sep 30, 2025, up from $3.598M at Dec 31, 2024 |
| Net Cash from Financing | $7.924M | For nine months ended Sep 30, 2025, crucial for liquidity |
| Revenue Decrease | 69% | Year-over-year decline in total revenue for nine months ended Sep 30, 2025 |
| Product Revenue Decrease | 48.7% | For nine months ended Sep 30, 2025, to $541K from $1.054M |
| Grant & Contract Revenue Decrease | 85.5% | For nine months ended Sep 30, 2025, to $187K from $1.291M |
| Armor Exit Costs | $4.457M | Expense in 2024, absent in 2025, contributing to reduced operating expenses |
| Common Shares Outstanding | 3,851,956 | As of November 7, 2025, indicating significant dilution |
| Net Loss Per Share (Basic) | $1.19 | For three months ended Sep 30, 2025, improved from $6.96 in 2024 |
| SEC File Number | 001-33624 | Identifies the company's filing with the SEC. |
| Fiscal Year End | 1231 | Indicates the end of the company's annual accounting period. |
| Cash Used in Operating Activities | $3.71 million | for six months ended June 30, 2025, an improvement from $4.95 million in 2024 |
| Accumulated Deficit | $286 million | as of June 30, 2025, up from $281.7 million as of December 31, 2024 |
| Proceeds from Equity Issuance | $4.38 million | from common stock and prefunded warrants, net of cash fees, for six months ended June 30, 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Sintx Technologies, Inc. (SINT)?
Sintx Technologies, Inc. has 50 recent SEC filings from Jan 2024 to Dec 2025, including 34 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SINT filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 45 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Sintx Technologies, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sintx Technologies, Inc. (SINT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sintx Technologies, Inc.?
Key financial highlights from Sintx Technologies, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SINT?
The investment thesis for SINT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sintx Technologies, Inc.?
Key executives identified across Sintx Technologies, Inc.'s filings include Chief Executive Officer, Eric Olson, B. Sonny Bal, Dr. Robert L. Johnson, Mr. David L. Johnson and 11 others.
What are the main risk factors for Sintx Technologies, Inc. stock?
Of SINT's 41 assessed filings, 3 were flagged high-risk, 27 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Sintx Technologies, Inc.?
Forward guidance and predictions for Sintx Technologies, Inc. are extracted from SEC filings as they are enriched.